This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Robert J. Joynt, MD, PhD

JAMA. 1990;263(19):2660-2661.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

A major theme in neurology for the last several years has been clinical trials of therapy for disorders that were thought to be untreatable. The course of Parkinson's disease, for example, has been greatly modified by the introduction of therapies that increase activity in the dopaminergic system. During this last year, another approach to this disease has been undertaken through attempts to delay and slow its manifestations. The variable course and heterogeneous manifestations of Parkinson's disease make clinical trials difficult. However, a multicenter controlled clinical trial with many safeguards was devised.¹ The clinical trial is still in progress, but the interim results show that 10 mg/d of selegiline (Deprenyl), a monoamine oxidase inhibitor, slowed the end point, which was a decision to treat the patient with levodopa therapy. The treatment also had a significant effect in slowing the time until it was necessary for the patient to give up . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?